Central AsianResearch Index

Влияние комбинированной патогенетической терапии на динамику толщины эпикардиального жира у пациентов с ишемической болезнью сердца и метаболическим синдромом

Aim. To evaluate the influence of combined hypolipidemic therapy (statins in combination with ezetimibe and fenofibrate) and sodium-glucose cotransporter 2 inhibitors on epicardial fat thickness in patients with coronary heart disease and metabolic syndrome. Materials and methods: The study included 49 patients with coronary heart disease and metabolic syndrome who underwent treatment at the Republican Specialized Scientific and Practical Medical Center of Cardiology. The patients were divided into 2 groups: 1) intensive statin therapy in combination with ezetimibe, 2) with the addition of fenofibrate and SGLT2 inhibitors. All patients underwent biochemical tests and imaging marker assessments, followed by comparison of the dynamics within and between groups. Results. When comparing two groups receiving different types of therapy, both groups demonstrated a significant decrease in lipid parameters: LDL-C p<0.001, TC p<0.001, TG p<0.001. Additionally, the group treated with fenofibrate and SGLT2 inhibitors showed a more significant reduction in epicardial fat (11.4 mm in the first group and 10.4 mm in the second group, p<0.05). Conclusion: Pathogenetic therapy with the inclusion of fenofibrate and SGLT2 inhibitors more effectively reduces the level of EFT, as well as TG, VLDL-C, and the TG/HDL index.

Сведения

Опубликовано
2025 · Т. 2, № 3, С. 199-208
Язык
Русский
ISSN
3060-4850
Издатель
Republican Specialized Scientific-Practical Medical Center of Cardiology